52 research outputs found
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
<p>Abstract</p> <p>Background</p> <p>The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies.</p> <p>Methods</p> <p>We determined the tumour mutation status of the entire tyrosine kinase (TK) domain of the EGFR and HER2-neu genes in a cohort of 52 patients with invasive epithelial ovarian cancer as well as the gene copy number and protein expression of both genes in 31 of these patients by DGGE and direct sequecing, immunohistochemistry and Fluorescent in Situ Hybridisation (FISH).</p> <p>Results</p> <p>The EGFR was expressed in 59% of the cases, with a 2+/3+ staining intensity in 38%. HER2-neu expression was found in 35%, with a 2/3+ staining in 18%. No mutations were found in exons 18–24 of the TK domains of EGFR and HER2-neu. High polysomy of the EGFR gene was observed in 13% of the invasive epthelial cancers and amplification of the HER2-neu gene was found in 10% and correlated with a high expression level by immunohistochemistry.</p> <p>Mutations within the tyrosine kinase domain were not found in the entire TK domain of both genes, but have been found in very rare cases by others.</p> <p>Conclusion</p> <p>Genomic alteration of the HER2-neu and EGFR genes is frequent (25%) in ovarian cancer. EGFR/HER2-neu targeted therapies should be investigated prospectively and specifically in that subset of patients.</p
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice
Background: Alzheimer’s disease (AD) brain shows an ongoing inflammatory condition and non-steroidal antiinflammatories
diminish the risk of suffering the neurologic disease. Cannabinoids are neuroprotective and antiinflammatory
agents with therapeutic potential.
Methods: We have studied the effects of prolonged oral administration of transgenic amyloid precursor protein
(APP) mice with two pharmacologically different cannabinoids (WIN 55,212-2 and JWH-133, 0.2 mg/kg/day in the
drinking water during 4 months) on inflammatory and cognitive parameters, and on 18F-fluoro-deoxyglucose
(18FDG) uptake by positron emission tomography (PET).
Results: Novel object recognition was significantly reduced in 11 month old Tg APP mice and 4 month
administration of JWH was able to normalize this cognitive deficit, although WIN was ineffective. Wild type mice
cognitive performance was unaltered by cannabinoid administration. Tg APP mice showed decreased 18FDG
uptake in hippocampus and cortical regions, which was counteracted by oral JWH treatment. Hippocampal GFAP
immunoreactivity and cortical protein expression was unaffected by genotype or treatment. In contrast, the density
of Iba1 positive microglia was increased in Tg APP mice, and normalized following JWH chronic treatment. Both
cannabinoids were effective at reducing the enhancement of COX-2 protein levels and TNF-a mRNA expression
found in the AD model. Increased cortical b-amyloid (Ab) levels were significantly reduced in the mouse model by
both cannabinoids. Noteworthy both cannabinoids enhanced Ab transport across choroid plexus cells in vitro.
Conclusions: In summary we have shown that chronically administered cannabinoid showed marked beneficial
effects concomitant with inflammation reduction and increased Ab clearanceThis work was supported by the Spanish Ministry of Science and
Technology (SAF 2005-02845 to M.L.C). A.M.M-M. was recipient a fellowship
from the Ministry of Education and Scienc
Anaerobic digestion and gasification of seaweed
The potential of algal biomass as a source of liquid and gaseous biofuels is a highly topical theme, with over 70 years of sometimes intensive research and considerable financial investment. A wide range of unit operations can be combined to produce algal biofuel, but as yet there is no successful commercial system producing such biofuel. This suggests that there are major technical and engineering difficulties to be resolved before economically viable algal biofuel production can be achieved. Both gasification and anaerobic digestion have been suggested as promising methods for exploiting bioenergy from biomass, and two major projects have been funded in the UK on the gasification and anaerobic digestion of seaweed, MacroBioCrude and SeaGas. This chapter discusses the use of gasification and anaerobic digestion of seaweed for the production of biofuel
De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures.
Next-generation sequencing has been invaluable in the elucidation of the genetic etiology of many subtypes of intellectual disability in recent years. Here, using exome sequencing and whole-genome sequencing, we identified three de novo truncating mutations in WAS protein family member 1 (WASF1) in five unrelated individuals with moderate to profound intellectual disability with autistic features and seizures. WASF1, also known as WAVE1, is part of the WAVE complex and acts as a mediator between Rac-GTPase and actin to induce actin polymerization. The three mutations connected by Matchmaker Exchange were c.1516C>T (p.Arg506Ter), which occurs in three unrelated individuals, c.1558C>T (p.Gln520Ter), and c.1482delinsGCCAGG (p.Ile494MetfsTer23). All three variants are predicted to partially or fully disrupt the C-terminal actin-binding WCA domain. Functional studies using fibroblast cells from two affected individuals with the c.1516C>T mutation showed a truncated WASF1 and a defect in actin remodeling. This study provides evidence that de novo heterozygous mutations in WASF1 cause a rare form of intellectual disability
- …